AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04111328
Drug: intravenous sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The PCA pumps contain sufentanil . And the pump is connected to participants intravenously .
Trial: NCT04111328
Drug: subcutaneous sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The PCA pumps contain sufentanil. And the pump is connected to participants subcutaneously.
Trial: NCT04111328
Drug: intravenous sufentanil and dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The PCA pumps contain sufentanil and dexmedetomidine. And the pump is connected to participants intravenously .
Trial: NCT04111328
Drug: subcutaneous sufentanil and dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The PCA pumps contain sufentanil and dexmedetomidine. And the pump is connected to participants subcutaneously.
Trial: NCT01080625
Drug: epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mcg of epinephrine (volume 10 ml) is administered iv at the time of reperfusion
Trial: NCT02171806
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01652417
Drug: methylprednisolone bolus IV 15 mg/kg/d for 3 days.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methylprednisolone bolus IV 15 mg/kg/d for 3 days.
Trial: NCT03433586
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill (visually identical to aspirin pill) to be taken daily for 10-14 days
Trial: NCT01034514
Drug: TECHNETIUM TC 99M MAA
RxNorm normalized name: TECHNETIUM TC 99M MAA UNIT DOSE INJ,SUSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mCi; iv
Trial: NCT00901901
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching erlotinib placebo 150 mg once daily
Trial: NCT00382044
Drug: Eprex; Neorecormon; Aranesp
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01837472
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the placebo group received the placebo capsule twice daily after meal for 14 consecutive days.
Trial: NCT00757081
Drug: phosphatidylcholine and deoxycholate
RxNorm normalized name: deoxycholate
DrugBank: Deoxycholic acid (DB03619)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg phosphatidylcholine, 42 mg deoxycholate subcutaneous injection Every 8 weeks x 2 with additional 2 treatments optional
Trial: NCT03373708
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600mg/m2
Trial: NCT00542035
Drug: ARRY-371797, p38 inhibitor; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose 1, dose 2
Trial: NCT00542035
Drug: Placebo; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose 1, dose 2
Trial: NCT00542035
Drug: Placebo; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose 1
Trial: NCT00542035
Drug: ARRY-371797, p38 inhibitor; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose 2
Trial: NCT01673555
Drug: GSK1278863
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1278863
Trial: NCT01673555
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00282971
Drug: Inhaled Insulin (Exubera)
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of inhaled insulin to pre-existing oral diabetes therapy.
Trial: NCT01319981
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m2 by vein over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2) for courses 1, 3, 5, 7
Trial: NCT01319981
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 by vein over 24 hours on day 4 after last dose of Cyclophosphamide for courses 1, 3, 5, 7
Trial: NCT01319981
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m2 IV over 2 hrs followed by 800 mg/m2 over 22 hrs on day 1 beginning after the completion of rituximab for Courses 2, 4, 6, and 8.
Trial: NCT01662167
Drug: Single
RxNorm normalized name: Singlet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the single dose regimen, 50 mg/m2 intramuscular methotrexate was given on day one and hCG level was measured on days four and seven. If the hCG level did not decrease by 15% between day four and seven, a second dose of methotrexate was injected on day seven, hCG level was measured weekly until a level of 15 mlU/ml or less was achieved
Trial: NCT02386020
Drug: placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After SRP, placebo gel was delivered subgingivally into periodontal pockets.
Trial: NCT02458742
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5%Hyperbaric bupivacaine 2 ml for spinal anesthesia
Trial: NCT00282763
Drug: MK0686
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00879060
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: spironolactone 50mg daily
Trial: NCT00879060
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inactive placebo pill daily
Trial: NCT01756833
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg po bid
Trial: NCT01756833
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule identical to the doxycycline capsule
Trial: NCT00443040
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was provided in coated tablets identical in appearance to asimadoline tablets. Subjects were given 3 tablets of placebo 90 minutes prior to their operation and then 3 placebo tablets b.i.d. for up to 10 post-operative doses.
Trial: NCT03778242
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo ampoules to TA in 100 ml saline by slow infusion
Trial: NCT04346095
Drug: Oral Sedatives with or Without Analgesia
RxNorm normalized name: E-Z Scrub with Ultradex Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will receive oral triazolam with topical proparacaine and sub-tenon's mixture of lidocaine and marcaine.
Trial: NCT04346095
Drug: Intravenous Sedatives with or Without Analgesia
RxNorm normalized name: E-Z Scrub with Ultradex Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will receive intravenous midazolam, propofol or fentanyl with topical proparacaine and sub-tenon's mixture of lidocaine and marcaine.
Trial: NCT04674293
Drug: Revelisa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy for patients with ischemic stroke
Trial: NCT01432665
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)
Trial: NCT03482635
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for infusion
Trial: NCT01432665
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)
Trial: NCT04541303
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride
Trial: NCT00152841
Drug: Iron supplement 300-600 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01441843
Drug: NaCl 0.9% (Sodium Chloride)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once 1ml \<75kg body weight, 1.5ml 75kg or \>75kg body weight, IV, before surgery
Trial: NCT00307892
Drug: Traumeel S: intra-operative irrigation + oral ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: homeopathic remedy
Trial: NCT00307892
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo remedy
Trial: NCT03858686
Drug: Placebo FP-025 capsules
RxNorm normalized name: PLACEBO CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo FP-025 capsules, BID will be administered to subjects in either Period 1 or Period 2, and given for 12 consecutive dosing days.
Trial: NCT01889667
Drug: ORMD-0801 Dose # 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Insulin Formulation
Trial: NCT01889667
Drug: ORMD-0801 Dose # 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Insulin Formulation
Trial: NCT01889667
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oil Capsules
Trial: NCT03169244
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be initiated on Day 1 and continue throughout the course of the study.
Trial: NCT04458636
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04151940
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive standard of care chemotherapy
Trial: NCT00961155
Drug: cyklezonid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mcg once daily
Trial: NCT00961155
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluticasone placebo twice daily, montelukast placebo once daily
Trial: NCT02608944
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine: 0.14mg/kg/min for 6 min. IV injection for MRI perfusion
Trial: NCT01469221
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 weekly multi-instillation of matching placebo in 40mL
Trial: NCT03106571
Drug: Pomaglumetad methionil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets twice daily
Trial: NCT03106571
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-4 tablets twice daily
Trial: NCT03547778
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group will receive placebo pessaries to be inserted vaginally the night before the procedure.
Trial: NCT02016196
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 placebo caps per day morning and night, during 15 days before TIPS and 6 months after TIPS
Trial: NCT04297865
Drug: A dose as CJ-15314
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A dose as CJ-15314, 1 capsule
Trial: NCT04297865
Drug: B dose as CJ-15314
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B dose as CJ-15314, 1 capsule
Trial: NCT04297865
Drug: C dose as CJ-15314
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C dose as CJ-15314, 1 capsule
Trial: NCT04297865
Drug: D dose as CJ-15314
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D dose as CJ-15314, 2 capsules
Trial: NCT04297865
Drug: E dose as CJ-15314
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E dose as CJ-15314, 1 capsule
Trial: NCT04297865
Drug: F dose as CJ-15314
RxNorm normalized name: F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F dose as CJ-15314, 2 capsules
Trial: NCT04297865
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 1 capsule
Trial: NCT04297865
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 2 capsules
Trial: NCT00566735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg, 2 times a day
Trial: NCT03382717
Drug: Loceryl 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 application per week during 6 months
Trial: NCT01952132
Drug: OMS643762
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02415829
Drug: capecitabine plus oxaliplatin
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The neoadjuvant chemotherapy consisted of oxaliplatin, 130 mg/m² on day 1, with capecitabine, 1000 mg/m² twice daily for 14 days every 3 weeks (the XELOX regimen)
Trial: NCT01952132
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01614522
Drug: ASLAN001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASLAN001 500mg BID
Trial: NCT03990285
Drug: Axumin, Intravenous Solution
RxNorm normalized name: Axumin, intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To compare 18F-fluciclovine PET uptake measures in glioblastoma patients with tumor progression versus pseudoprogression
Trial: NCT04339348
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inert placebo cream will be applied on the cervix at the time of LNG-IUD insertion plus vaginal placebo tablet 3 hours before LNG-IUD insertion
Trial: NCT00964730
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered three times a day over 9 days and a single dose administered on Day 10
Trial: NCT03573518
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00069901
Drug: CT-2103 (poly(L)glutamate-paclitaxel)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00468806
Drug: GSK598809, using [11C]-(+)-PHNO
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00891332
Drug: S-1 plus LV (The combination therapy of S-1 and Leucovorin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 40-60 mg bid day 1～day 7 LV 25 mg bid day 1～day 7
Trial: NCT02213744
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01723241
Drug: XAF5, concentration A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01723241
Drug: XAF5, concentration B
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01723241
Drug: XAF5, concentration C
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01723241
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02530827
Drug: use of lipid-lowering drugs.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients shoud be in use of a lipid-lowering drugs previouly, at least one month before of the begining of the study.
Trial: NCT00268476
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00268476
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00268476
Drug: ADT
RxNorm normalized name: Radtue
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00268476
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00268476
Drug: Transdermal Oestradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00184795
Drug: 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet per day for 24 weeks
Trial: NCT01323933
Drug: AB0024
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of different dosages of drug
Trial: NCT02268760
Drug: BILN 2061 ZW single rising doses
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00184795
Drug: 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet per day for 24 weeks
Trial: NCT00184795
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets for 24 weeks
Trial: NCT01527123
Drug: GSK2585823
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLDM1%/BPO3%
Trial: NCT02567656
Drug: RP6530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet starting at 200 mg
Trial: NCT04146129
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single infusion of normal saline
Trial: NCT01822249
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03567941
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet orally administered under fasting
Trial: NCT03567941
Drug: Hydrocodon bitartrate-acetaminophen arm 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet orally administered under fasted conditions
Trial: NCT03567941
Drug: Hydrocodon bitartrate-acetaminophen arm 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet orally administered under fed conditions
Trial: NCT03567941
Drug: Reference
RxNorm normalized name: Loreal Preference Dark Auburn 4R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet orally administered under fasted conditions
Trial: NCT00520091
Drug: CPT- 11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 65mg/m2 given on days 1, 8 ,22 and 29 prior to surgery
Trial: NCT00520091
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg, orally, twice per day beginning on day minus 3 and continue until the end of chemoradiation with CPT-11 and Cisplatin
Trial: NCT01149369
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant-placebo, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks
Trial: NCT01424397
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo intranasal
Trial: NCT01601990
Drug: Placebo group(once daily)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks.
Trial: NCT01601990
Drug: LC15-0444 50mg qd
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks
Trial: NCT00472043
Drug: PDT with Metvix 160 mg/g cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00472043
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01529827
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01935167
Drug: DW1029M 600mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DW1029M 150mg 2 tablets b.i.d
Trial: NCT01935167
Drug: DW1029M 1200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DW1029M 300mg 2 tablets b.i.d
Trial: NCT01624974
Drug: MK-1029
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-1029 150 mg tablets taken QD
Trial: NCT01624974
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets (matching the MK-1029 150 mg tablets) QD
Trial: NCT02875366
Drug: LUM/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02875366
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02463331
Drug: azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: azathioprine 1-2mg/Kg/day until the end of the study
Trial: NCT02545049
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to be taken orally, once daily.
Trial: NCT03550378
Drug: MEDI0382
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive subcutaneous MEDI0382 titrated from 50 μg upto 300 μg (50 μg once daily for 4 days, followed by 100 μg daily for 7 days, 200 μg daily for 7 days, and 300 μg daily for 14 days) for 32 days.
Trial: NCT03550378
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive SC placebo matched to MEDI0382 once daily for 32 days.
Trial: NCT00343265
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT04203511
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intravenously every 3 weeks on Day 1 of each 21-day cycle for 4 cycles, followed by a consolidation part of placebo administered intravenously on Day 1 of each 28-day cycle for up to 12 cycles.
Trial: NCT03917303
Drug: standard step-up care
RxNorm normalized name: STEP 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conventional step-up care starting with corticosteroids
Trial: NCT00790426
Drug: TKI258
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00056095
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03780049
Drug: H101
RxNorm normalized name: Avicel PH101 (Microcrystalline Cellulose NF) for Compounding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive H101 0.5ml dissolved in 10ml normal saline in each session of HAIC
Trial: NCT03780049
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive normal saline 10ml in each session of HAIC
Trial: NCT01140841
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 to 2 tablets three times per day to be taken according to the same schedule as the active study drug.